Viking Therapeutics advances VK2735 to Phase 3; shares dip
Viking Therapeutics advanced obesity drug VK2735 to Phase 3 after Phase 2 showed ~15% mean weight loss at the top dose. The company says two fully enrolled Phase 3 trials target topline data in H2 2027; shares dipped ~1% on the news.